Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Wave Life Sciences Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wave Life Sciences wird ein Gewinn- und Umsatzwachstum von 12.4% bzw. 29.8% pro Jahr prognostiziert, während der Gewinn pro Aktie um 20.3% pro Jahr wachsen soll.

Wichtige Informationen

12.4%

Wachstumsrate der Gewinne

20.3%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum23.9%
Wachstumsrate der Einnahmen29.8%
Zukünftige Eigenkapitalrenditen/a
Analystenabdeckung

Good

Zuletzt aktualisiert15 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

We Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business Growth

Apr 09
We Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business Growth

Wave Life Sciences' Weighty Ambition: Carving Out Obesity Niche

Mar 09

Wave Life Sciences Ltd.'s (NASDAQ:WVE) 30% Price Boost Is Out Of Tune With Revenues

Mar 03
Wave Life Sciences Ltd.'s (NASDAQ:WVE) 30% Price Boost Is Out Of Tune With Revenues

We're Interested To See How Wave Life Sciences (NASDAQ:WVE) Uses Its Cash Hoard To Grow

Sep 13
We're Interested To See How Wave Life Sciences (NASDAQ:WVE) Uses Its Cash Hoard To Grow

Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Cut Their EPS Forecasts Substantially

May 08
Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Cut Their EPS Forecasts Substantially

Here's Why Wave Life Sciences (NASDAQ:WVE) Must Use Its Cash Wisely

Mar 30
Here's Why Wave Life Sciences (NASDAQ:WVE) Must Use Its Cash Wisely

Are Investors Undervaluing Wave Life Sciences Ltd. (NASDAQ:WVE) By 47%?

Jan 20
Are Investors Undervaluing Wave Life Sciences Ltd. (NASDAQ:WVE) By 47%?

Some Analysts Just Cut Their Wave Life Sciences Ltd. (NASDAQ:WVE) Estimates

Nov 11
Some Analysts Just Cut Their Wave Life Sciences Ltd. (NASDAQ:WVE) Estimates

Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Deliver On Growth Plans?

Aug 12
Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Deliver On Growth Plans?

Wave Life Sciences Q2 2022 Earnings Preview

Aug 10

Will Wave Life Sciences (NASDAQ:WVE) Spend Its Cash Wisely?

Apr 21
Will Wave Life Sciences (NASDAQ:WVE) Spend Its Cash Wisely?

Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Invest In Growth?

Jan 11
Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Invest In Growth?

We Think Wave Life Sciences (NASDAQ:WVE) Needs To Drive Business Growth Carefully

Sep 24
We Think Wave Life Sciences (NASDAQ:WVE) Needs To Drive Business Growth Carefully

What Does The Future Hold For Wave Life Sciences Ltd. (NASDAQ:WVE)? These Analysts Have Been Cutting Their Estimates

Aug 07
What Does The Future Hold For Wave Life Sciences Ltd. (NASDAQ:WVE)? These Analysts Have Been Cutting Their Estimates

Wave Life Sciences posts proof-of-concept data from genetic disorder study

Jun 02

Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Slashed This Year's Estimates

May 15
Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Slashed This Year's Estimates

Things Look Grim For Wave Life Sciences Ltd. (NASDAQ:WVE) After Today's Downgrade

Apr 02
Things Look Grim For Wave Life Sciences Ltd. (NASDAQ:WVE) After Today's Downgrade

Wave Life Sciences (NASDAQ:WVE) Share Prices Have Dropped 80% In The Last Three Years

Feb 19
Wave Life Sciences (NASDAQ:WVE) Share Prices Have Dropped 80% In The Last Three Years

Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Deliver On Growth Plans?

Jan 13
Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Deliver On Growth Plans?

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:WVE - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/202689-119-189-1376
12/31/202551-139-135-1267
12/31/202468-119-131-1167
3/31/2024113-62-139-138N/A
12/31/2023113-58-21-19N/A
9/30/202385-85-21-20N/A
6/30/202337-131-12-11N/A
3/31/202315-151-4-2N/A
12/31/20224-162-129-128N/A
9/30/20224-153-103-101N/A
6/30/202240-120-105-104N/A
3/31/202243-118-85-84N/A
12/31/202141-122-90-89N/A
9/30/202149-116-114-113N/A
6/30/202116-143-106-105N/A
3/31/202116-145-135-134N/A
12/31/202020-150-117-116N/A
9/30/202013-178-148-146N/A
6/30/202013-196-172-169N/A
3/31/202017-197-168-164N/A
12/31/201916-194-192-188N/A
9/30/201917-175-166-160N/A
6/30/201919-162-154-145N/A
3/31/201916-156-50-41N/A
12/31/201814-147-33-23N/A
9/30/201812-140-23-13N/A
6/30/20189-127-20-7N/A
3/31/20185-116-115-99N/A
12/31/20174-102N/A-84N/A
9/30/20173-90N/A-74N/A
6/30/20173-82N/A-63N/A
3/31/20172-69N/A-42N/A
12/31/20161-56N/A-32N/A
9/30/20161-44N/A-25N/A
6/30/20160-31N/A-16N/A
3/31/20160-24N/A-18N/A
12/31/20150-19N/A-13N/A
9/30/20150-14N/A-7N/A
6/30/20150-10N/A-5N/A
3/31/20150-8N/A-5N/A
12/31/2014N/A-5N/A-4N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: WVE wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: WVE wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: WVE wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: WVEDie Einnahmen des Unternehmens (29.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.4% pro Jahr).

Hohe Wachstumseinnahmen: WVEDie Einnahmen des Unternehmens (29.8% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.


Wachstumsprognosen für den Gewinn je Aktie


Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von WVE in 3 Jahren voraussichtlich hoch sein wird


Wachstumsunternehmen entdecken